IPHA Innate Pharma SA IFRS Annual reports only
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1598599 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | 9.01M | 20.12M |
| R&D expense | 43.62M | 51.98M |
| SG&A expense | 19.39M | 19.72M |
| Operating income | -54.01M | -51.58M |
| Interest expense | 440,000 | 566,000 |
| Pretax income | -49.18M | -49.47M |
| Income tax | 0 | 0 |
| Net income | -49.18M | -49.47M |
| EBITDA | -52.62M | -49.59M |
| EPS (basic) | -0.55 | -0.61 |
| EPS (diluted) | -0.55 | -0.61 |
| Balance sheet | ||
| Cash & equivalents | 28.09M | 66.40M |
| Short-term investments | 6.22M | 14.38M |
| Receivables | 12.40M | 4.97M |
| Current assets | 46.71M | 85.74M |
| PP&E, netmay include right-of-use assets (IFRS) | 4.36M | 5.13M |
| Intangibles | 0 | 0 |
| Total assets | 62.72M | 111.06M |
| Current liabilities | 36.65M | 32.98M |
| Total liabilities | 84.42M | 102.22M |
| Shareholders' equity | -21.70M | 8.83M |
| Cash flow statement | ||
| Operating cash flow | -52.76M | -6.90M |
| Capital expenditure | 140,000 | 391,000 |
| Free cash flow | -52.90M | -7.29M |
| Investing cash flow | 7.29M | 9.20M |
| Financing cash flow | 6.07M | -6.01M |
| Depreciation & amortization | 1.38M | 1.99M |
| Stock-based compensation | 2.57M | 3.94M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.